Efficacy was partly mediated by transplant-based replacement of astrocyte GLT1, presumably via restoration of extracellular glutamate homeostasis by preventing ALS-associated loss of GLT1. Here, SLC1A2 is linked to amyotrophic lateral sclerosis.